⌘K
t
Tissue Regenix Group plc announced that on 4 April 2023, Chief Executive Officer Daniel Lee and Chief Financial Officer David Cocke each purchased 1,428,570 of the Company's ordinary shares of 0.1p. These transactions, valued at £8,096.42 each, took place on the London Stock Exchange, AIM Market, resulting in Daniel Lee holding 8,690,770 shares (0.12%) and David Cocke holding 7,120,570 shares (0.10%).
| Date | 5 Apr 2023 |
| Time | 07:00:05 |
| Category | Director/PDMR dealings |
| ID | 3905V |
Tissue Regenix Group plc
('Tissue Regenix' or the 'Company')
CEO and CFO Share Purchases
Tissue Regenix (AIM: TRX), the regenerative medical device company, announces that on 4 April 2023, Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer each purchased 1,428,570 of the Company's ordinary shares of 0.1p each ("Ordinary Shares").
|
Name |
Title |
Number of Ordinary Shares purchased |
Resulting beneficial interest in the Company's Ordinary Shares |
Percentage of Company's Total Voting Rights |
|
Daniel Lee |
Chief Executive Officer |
1,428,570 |
8,690,770 |
0.12% |
|
David Cocke |
Chief Financial Officer |
1,428,570 |
7,120,570 |
0.10% |
For more information:
|
Tissue Regenix Group plc |
||
|
David Cocke, Chief Financial Officer |
Via Walbrook PR |
|
|
|
|
|
|
finnCap Ltd (Nominated Adviser and Broker) |
|
|
|
Emily Watts/Geoff Nash/George Dollemore - Corporate Finance |
|
|
|
Nigel Birks/Harriet Ward - ECM |
|
|
|
|
|
|
|
Walbrook PR (Financial PR & IR) |
Tel: +44(0)20 7933 8780 |
|
|
Alice Woodings / Lianne Applegarth |
TissueRegenix@walbrookpr.com |
|
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in the field of regenerative medicine. The Company's patented decellularisation technology ('dCELL®') removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or damaged body structures. Current applications address many critical clinical needs in sports medicine, foot and ankle and wound care.
In August 2017, Tissue Regenix acquired CellRight Technologies®, a biotech company that specialises in regenerative medicine and is dedicated to the development of high quality, innovative tissue scaffolds, which can enhance healing opportunities in defects created by trauma and disease. CellRight®'s human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
Daniel Lee
|
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Chief Executive Officer |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
Tissue Regenix Group plc |
|||
|
b)
|
LEI
|
213800PNOD5UHQUFJI36 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares of 0.1p each |
|||
|
|
|
||||
|
Identification code |
GB00B5SGVL29 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Purchase |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
0.5700p |
500,000 |
|
|
|
|
|
0.5650p |
928,570 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
1,428,570 |
||||
|
|
|
||||
|
- Price |
£8,096.42 |
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
4 April 2023 |
|||
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM Market |
|||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
David Cocke
|
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Chief Financial Officer |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
Tissue Regenix Group plc |
|||
|
b)
|
LEI
|
213800PNOD5UHQUFJI36 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares of 0.1p each |
|||
|
|
|
||||
|
Identification code |
GB00B5SGVL29 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Purchase |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
0.5700p |
500,000 |
|
|
|
|
|
0.5650p |
928,570 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
1,428,570 |
||||
|
|
|
||||
|
- Price |
£8,096.42 |
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
4 April 2023 |
|||
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM Market |
|||